

# **Human OX40 Ligand/TNFSF4 Antibody**

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1054


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human OX40 Ligand/TNFSF4 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant mouse OX40 Ligand/TNFSF4 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human OX40 Ligand/TNFSF4 Gln51-Leu183 Accession # Q6FGS4		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.		

### **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 μg/mL	Recombinant Human OX40 Ligand/TNFSF4 (Catalog # 1054-OX)
Neutralization	Measured by its ability to neutralize OX40 Ligand/TNFSF4-induced proliferation in human peripheral blood mononuclear cells (PBMC). The Neutralization Dose (ND <sub>50</sub> ) is typically 0.03-0.12 μg/mL in the presence of 10 ng/mL Recombinant Human OX40 Ligand/TNFSF4, 10 μg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody, and 0.2 μg/mL PHA.	

#### DATA



Cell Proliferation Induced by OX40 Ligand/TNFSF4 and Neutralization by Human OX40 Ligand/TNFSF4 Antibody.

In the presence of a cross-linking in the presence of a cross-linking.

In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050) and PHA (0.2 µg/mL), Recombinant Human OX40 Ligand/TNFSF4 (Catalog # 1054-OX) stimulates proliferation in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line). Under these conditions, proliferation elicited by Recombinant Human OX40 Ligand/TNFSF4 (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human OX40 Ligand/TNFSF4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1054). The  $\mathrm{ND}_{50}$  is typically  $0.03\text{-}0.12~\mu g/mL.$ 

# PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.



# **Human OX40 Ligand/TNFSF4 Antibody**



Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1054

## **BACKGROUND**

OX40 Ligand (OX40L), also known as gp34, is a type II transmembrane glycoprotein belonging to the TNF superfamily. Human OX40L cDNA encodes a 183 amino acids (aa) polypeptide with an amino-terminal cytoplasmic domain (aa 1-23) and a carboxy-terminal extracellular domain (aa 51-183). It shares 46% aa sequence identity with the mouse counterpart. OX40L is expressed on the surface of activated B cells, T cells, dendritic cells, and endothelial cells. Similarly to other TNF superfamily members, membrane-bound OX40 Ligand exists as a homotrimer. OX40L binds to OX40 (CD134), a member of the TNF receptor superfamily that is expressed predominantly on activated CD4+ T cells. OX40 Ligand is one of the co-stimulatory molecules in the immune system that includes B7, CD40 Ligand, CD30 Ligand, CD27 Ligand, and 4-1BB Ligand. Because OX40 appears as a late activation-induced T cell surface antigen, it has been speculated that the major function of OX40-OX40L interaction is to transmit a late co-stimulatory signal to promote the survival and proliferation of activated CD4+ T cells and prolong the immune response. Engagement of OX40 on activated T cells *in situ* in tumors has been shown to augment immune responses and subsequent tumor regression.

## References:

- 1. Godfrey, W.R. et al. (1994) J. Exp. Med. 180:757.
- 2. Baum, P.R. et al. (1994) EMBO J. **13**:3992.
- 3. Al-Shamkhani, A. et al. (1997) J. Biol. Chem. 272:5275.
- 4. Kjaergaard, J. et al. (2000) Cancer Res. 60:5514.

